Neonatal diabetes mellitus (NDM) is a rare disease requiring insulin treatment. Its treatment is primarily focused on maintaining adequate glycemic control and avoiding hypoglycemia. Although insulin pump therapy is frequently administered to adults and children, there is no consensus on the use of insulin pumps in NDM. A 10 day-old female infant was referred to us with intrauterine growth retardation and poor weight gain. Hyperglycemia was noted, and continuous intravenous insulin infusion was initiated. However, the patient's serum glucose levels fluctuated widely, and maintaining the intravenous route became difficult within the following weeks. Continuous subcutaneous insulin infusion with an insulin pump was introduced on the twenty-fifth day of life, and good glycemic control was achieved without any notable adverse effects including hypoglycemia. We suggest that the insulin pump is a safe and effective mode for treating NDM and its early adoption may shorten the length of hospital stays in patients with NDM.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027075PMC
http://dx.doi.org/10.6065/apem.2013.18.3.148DOI Listing

Publication Analysis

Top Keywords

insulin pump
16
insulin
8
pump therapy
8
neonatal diabetes
8
diabetes mellitus
8
glycemic control
8
hypoglycemia insulin
8
insulin infusion
8
therapy transient
4
transient neonatal
4

Similar Publications

Fear of hypoglycemia and sleep in children with type 1 diabetes and their parents.

Front Endocrinol (Lausanne)

December 2024

Department of Pediatric Diabetes and Endocrinology, Clinique Pédiatrique, Centre Hospitalier, Luxembourg, Luxembourg.

Aims: To compare impact of pump treatment and continuous glucose monitoring (CGM) with predictive low glucose suspend (SmartGuard) or user initiated CGM (iscCGM) on sleep and hypoglycemia fear in children with type 1 Diabetes and parents.

Methods: Secondary analysis of data from 5 weeks pump treatment with iscCGM (A) or SmartGuard (B) open label, single center, randomized cross-over study was performed. At baseline and end of treatment arms, sleep and fear of hypoglycemia were evaluated using ActiGraph and questionnaires.

View Article and Find Full Text PDF

Background: Insulin pumps coupled with continuous glucose monitoring sensors use algorithms to analyze real-time blood glucose levels. This allows for the suspension of insulin administration before hypoglycemic thresholds are reached or for adaptive tuning in hybrid closed-loop systems. This longitudinal retrospective study aims to analyze real-world glycemic outcomes in a pediatric population transitioning to such devices.

View Article and Find Full Text PDF

Introduction: While people with diabetes (PWD)'s experiences with their insulin delivery systems (IDS) are frequently reported in clinical trials, few real-world data exist on the subject. This study aimed to assess the real-world experience and satisfaction with IDS in PWD.

Methods: This cross-sectional survey of PWD treated with tubed or tubeless insulin pumps, hybrid closed loop (HCL) systems, or multiple daily injections (MDI) for at least 3 months ran from 4 to 16 May 2023.

View Article and Find Full Text PDF

Applying auricular magnetic therapy to decrease blood glucose levels and promote the healing of gangrene in diabetes patients: a case report.

J Med Case Rep

December 2024

Beijing Acupuncture and Chinese Herbology, 19 Edgemoor Road, Lutherville-Timonium, MD, 21093, USA.

Background: Magnetic therapy has demonstrated beneficial effects for reducing pain, nausea, neuropathy, and various other health concerns in the human body. To our knowledge, limited research has documented the use of auricular static magnetic therapy as a potential treatment for diabetes. This report presents the first evidence of using magnetic discs placed at acupuncture points on the human ear to decrease blood glucose levels and promote the healing of gangrene in diabetic patients.

View Article and Find Full Text PDF

Background: Older adults with type 1 diabetes are at risk for serious hypoglycemia. Automated insulin delivery can reduce risk but has not been sufficiently evaluated in this population.

Methods: We conducted a multicenter, randomized crossover trial in adults older than or equal to 65 years of age with type 1 diabetes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!